Analysts on Sarepta - Search News

Order byBest matchMost fresh

News

gene therapy, Sarepta and Europe

· 1h · on MSN

Sarepta fails to win EU backing for muscle disorder gene therapy

Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as the company faces intense regulatory scrutiny after two recent patient deaths tied to the treatment.

Continue reading

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy

BioPharma Dive · 10h

Sarepta woes mount as Duchenne gene therapy knocked back in Europe

11hon MSN

Goldman Sachs' Salveen Richter on Sarepta's ongoing troubles, opportunities in biotech

Salveen Richter, Goldman Sachs lead biotech analyst, joins 'Squawk Box' to discuss the troubles facing Sarepta and its ...

Sarepta’s Future Increasingly Uncertain as FDA Eyes New Study for Elevidys

CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...

4d

Sarepta Therapeutics stock sinks further Tuesday after halting shipment of bestselling drug Elevidys

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...

2d

Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label

Analysts downgraded Sarepta as FDA pause on Elevidys raises regulatory uncertainty, leading to significant stock pressure and ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results